Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial
Carcinoma, Small Cell
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-kit
Imatinib did not have antitumor activity against SCLC, even with c-kit protein present in tumor specimens. The dismal prognosis for these patients with progressive SCLC emphasized the urgent need for continued studies of new therapies in this population.